New natural PPAR-• agonist for childhood atopic dermatitis: Dermocorticoid-sparing and quality of life improvement

31 octobre 2022|
    Atopie
Introduction: Atopic dermatitis (AD) is associated with skin barrier disruption resulting from major lipids metabolism dysfunctions. Dermo-corticosteroids (DC) are used for AD flares but have potential side effects. PPAR-α (peroxysome-proliferative-activated receptors) are transcription factors involved in the regulation of epidermal homeostasis (differentiation, proliferation, inflammation…). A new emollient, containing a patented sunflower oleodistillate (SO), has been [...]
2006

Authors

Philippe Msika 1, Clarence de Belilovsky 2, Bernard Chadoutaud 3, François Nicolas 4.

Affiliations

1 Laboratoires Expanscience, Epernon, France ; 2 Institut Alfred Fournier, Paris, France ; 3 Clinreal Online, Toulouse, France ; 4 Inserm 503, Lyon, France

Introduction: Atopic dermatitis (AD) is associated with skin barrier disruption resulting from major lipids metabolism dysfunctions. Dermo-corticosteroids (DC) are used for AD flares but have potential side effects. PPAR-α (peroxysome-proliferative-activated receptors) are transcription factors involved in the regulation of epidermal homeostasis (differentiation, proliferation, inflammation…). A new emollient, containing a patented sunflower oleodistillate (SO), has been formulated for AD. We have previously shown that SO: (1) activates of PPAR-α in CV1 cells; (2) induces the synthesis of key epidermal lipids (eg, ceramides ×3, cholesterol ×2) in human skin explants; and (3) reduces TPA-induced inflammation (oedema and cytokines mRNA production).